Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 7, 2009, Pages 848-853

  Dujmovic, Irena ^a   Pekmezovic, Tatjana ^a   Obrenovic, Radmila ^a   Nikolić, Aleksandra ^b   Spasic, Mihailo ^b   Stojkovic, Marija Mostarica ^c   Drulovic, Jelena ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cerebrospinal fluid (CSF); Disease activity; Multiple sclerosis (MS); Serum; Uric acid (UA)

Indexed keywords

PEROXYNITRITE; URIC ACID;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL;

ADULT; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; URIC ACID;

EID: 67849104125     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.192     Document Type: Article

References (43)

1. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996;6: 259-74.
2. Mitrovic B, Ignarro LJ, Montestruque S, Smoll A, Merrill JE. Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience 1994;61:575-85.
3. Mitrovic B, Parkinson J, Merrill JE. An in vitro model of oligodendrocyte destruction by nitric oxide and its relevance to multiple sclerosis. Methods 1996;10:501-13.
4. Garthwaite G, Goodwin DA, Batchelor AM, Leeming K, Garthwaite J. Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve. Neuroscience 2002;109:145-55.
5. Bö L, Dawson TM, Wesselingh S, Mörk S, Choi S, Kong PA, et al. Induction of nitric oxide synthase in demyelin- ating regions of multiple sclerosis brains. Ann Neurol 1994;36:778-86.
6. Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, et al. Activation of the inducibile form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA 1995;92:12041-5.
7. De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, Van der Valk P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropath Exp Neur 1997;56:10-20.
8. Giovannoni G. Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Mult Scler 1998;4:27-30.
9. Giovannoni G, Silver NC, O'Riordan J, Miller RF, Heales SJ, Land JM, et al. Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease. Mult Scler 1999;5:335-41.
10. Drulović J, Dujmović I, Mesaros S, Samardzić T, Maksi- mović D, Stojsavljević N, et al. Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation with disease activity. Mult Scler 2001;7:19-22.
11. Beckman JS. Peroxynitrite versus hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann New J Acad Sci 1994;738:69-75.
12. Ischriopoulos H, Zhu L, Beckman JS. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Bio- chem Biophys 1992;298:446-51.
13. Barker JE, Bolaños JP, Land JM, Clark JB, Heales SJ. Glutathione protects astrocytes from peroxynitrite-medi- ated mitochondrial damage: implications for neuronal/ astrocytic trafficking and neurodegeneration. Dev Neurosci 1996;18:391-6.
14. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87:315-424.
15. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxi- dant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858-62.
16. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 1986; 235:747-54.
17. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, et al. Uric acid, a natural peroxynitrite scavenger, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998; 95:675-80.
18. Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes and tissue damage in a mouse model of multiple sclerosis. FASEB J 2000;14:691-8.
19. Spitsin SV, Scott GS, Kean RB, Mikheeva T, Hooper DC. Protection of myelin basic protein immunized mice from free-radical mediated inflammatory cell invasion of the central nervous system by the natural peroxynitrite scavenger uric acid. Neurosci Lett 2000;292:137-41.
20. Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol 2000;165:6511-8.
21. Drulović J, Dujmović I, Stojsavljević N, Mesaros S, And- jelković S, Miljković D, et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol 2001;248: 121-6.
22. Spitsin SV, Hooper DC, Mikheeva T, Koprowski H. Uric acid levels in patients with multiple sclerosis: analysis in mono- and dizygotic twins. Mult Scler 2001;7:165-6.
23. Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosur 2006;108: 527-31.
24. Spitsin S, Koprowski H. Role of uric acid in multiple sclerosis. Curr Top Microbiol Immunol 2008;318:325-42.
25. Lahoda F, Athen D. Typing of uric acid level in cerebro- spinal fluid in neurological and psychiatric diseases. Adv xp Med Biol 1977;76B:256-8.
26. Scott GS, Hooper DC. The role of uric acid in protection against peroxynitrite-mediated pathology. Medical Hypotheses 2001;56:95-100.
27. Stover JF, Lowitzsch K, Kempski OS. Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. Neurosci Lett 1997;238:25-8.
28. Kastenbauer S, Kieseier BC, Becker BF. No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis. J Neurol 2005;252:611-2.
29. Zamani A, Rezaei A, Khaeir F, Hooper DC. Serum and cerebrospinal fluid uric acid levels in multiple sclerosis patients. Clin Neurol Neurosur 2008;110:642-3.
30. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
31. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
32. Wortmann RL. Gout and other disorders of purine metabolism. In: Fauci SA, Braunwald E, Isselbacher JK, et al., editors. Harrison's principles of internal medicine. New York: McGraw-Hill, 1998;2158-66.
33. Becker BF, Kastenbauer S, Koodel U, Kiesl D, Pfister HW. Urate oxidation in CSF and blood of patients with inflammatory disorders of the nervous system. Nucleosides Nucleotides Nucleic Acids 2004;23:1201-4.
34. Knapp CM, Constantinescu CS, Tan JH, McLean R, Cher- ryman GR, Gottlob I. Serum uric acid levels in optic neuritis. Mult Scler 2004;10:278-80.
35. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006;180:17-28.
36. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178-201.
37. Guerrero AL, Martin-Polo J, Laherrán E, Gutiérrez F, Igle- sias F, Tejero MA, et al. Variation of serum uric acid levels in multiple sclerosis during relapses and immu- nomodulatory treatment. Eur J Neurol 2008;15:394-7.
38. Constantinescu CS, Freitag P, Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 2000;6:378-81.
39. Menge T, Weber MS, Hemmer B, Kieseier BC, von Budingen HC, Warnke C, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008;68:2445-68.
40. Toncev G, Milicic B, Toncev S, Samardzic G. High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 2002;40:505-8.
41. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxy-nitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 1997;94:2528-33.
42. Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol 2001;49:139.
43. Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowski H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 2001;7:313-9.